Jennifer Viera

Investor Relations Contact presso ENANTA PHARMACEUTICALS, INC.

Health Technology

Profilo

Jennifer Viera is currently the Head-Investor Relations & Communications at Enanta Pharmaceuticals, Inc. She previously worked as the Senior Director-Corporate Communications at OvaScience, Inc. and as the Investor & Media Contact at Tetraphase Pharmaceuticals, Inc.

Posizioni attive di Jennifer Viera

Società	Posizione	Inizio
ENANTA PHARMACEUTICALS, INC.	Investor Relations Contact	01/01/2023

Tutte le posizioni attive di Jennifer Viera

Precedenti posizioni note di Jennifer Viera

Società	Posizione	Fine
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Corporate Officer/Principal	-
TETRAPHASE PHARMACEUTICALS, INC.	Investor Relations Contact	-

Vedi nel dettaglio l'esperienza di Jennifer Viera

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Jennifer Viera

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ENANTA PHARMACEUTICALS, INC.	Health Technology

Aziende private	2
Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA.	Health Technology
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Health Technology